Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Johannes Francois Fahrmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5088-0198; OpenAlex author ID A5072417435; NIH RePORTER profile ID 14158591. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 8)
Trials
0
Grants
1
Labs led
1
Collaborators
77
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 2 papers, 1 grant

Papers 15

  1. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Last author DOI 10.64898/2026.08.06.26359908↗
  2. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Last author DOI 10.64898/2026.10.05.756824↗
  3. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Co-author DOI 10.1016/j.canlet.2025.217450↗
  4. Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progress… Last author DOI 10.1158/1078-0432.ccr-24-2931↗
  5. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  6. Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer. Last author DOI 10.1093/clinchem/hvad186↗
  7. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  8. A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer. Last author DOI 10.33696/cancerimmunol.6.095↗
  9. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Last author DOI 10.1016/j.xcrm.2023.101194↗
  10. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an ea… Last author DOI 10.1101/2023.08.14.553002↗
  11. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Last author DOI 10.1016/j.molmet.2021.101426↗
  12. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Co-author DOI 10.1053/j.gastro.2020.11.052↗
  13. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Co-author DOI 10.1158/1055-9965.epi-20-0161↗
  14. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. First author DOI 10.1200/po.19.00330↗
  15. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy126↗

Grants 1

  1. Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions R01CA299972↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 15 shared papers, 2019–2026 · strength 2.29
  2. Samir Hanash · 14 shared papers, 2019–2026 · strength 2.07
  3. Ehsan Irajizad · 12 shared papers, 2020–2026 · strength 1.95
  4. Jody V. Vykoukal · 11 shared papers, 2019–2026 · strength 1.67
  5. Jianjun Zhang · 7 shared papers, 2019–2025 · strength 1.13
  6. Ricardo A. Léon-Letelier · 5 shared papers, 2023–2026 · strength 0.94
  7. Michele Yip-Schneider · 6 shared papers, 2019–2025 · strength 0.91
  8. Christian Max Schmidt · 6 shared papers, 2019–2025 · strength 0.90
  9. Yihui Chen · 4 shared papers, 2022–2026 · strength 0.65
  10. Riccardo Ballarò · 3 shared papers, 2024–2026 · strength 0.62
  11. Brian Matthew Wolpin · 4 shared papers, 2021–2026 · strength 0.56
  12. Eugene Jon Koay · 2 shared papers, 2026 · strength 0.44
  13. Florencia M. McAllister · 2 shared papers, 2026 · strength 0.44
  14. Ziding Feng · 3 shared papers, 2019–2026 · strength 0.38
  15. Ana Babić · 3 shared papers, 2021–2024 · strength 0.35
  16. Andrea J. Bullock · 3 shared papers, 2021–2024 · strength 0.35
  17. Thomas E. Clancy · 3 shared papers, 2021–2024 · strength 0.35
  18. Kimmie Ng · 3 shared papers, 2021–2024 · strength 0.35
  19. Michael D. Kluger · 3 shared papers, 2021–2024 · strength 0.35
  20. Kunal Jajoo · 3 shared papers, 2021–2024 · strength 0.35
  21. John A. Chabot · 3 shared papers, 2021–2024 · strength 0.35
  22. Jeanine M. Genkinger · 3 shared papers, 2021–2024 · strength 0.35
  23. Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.35
  24. Randall E. Brand · 3 shared papers, 2019–2024 · strength 0.34
  25. Surinder K. Batra · 2 shared papers, 2020–2024 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.